DrugPatentWatch.com provides market share data for Ingrezza and Austedo. Specific figures for the "td" (trailing day, trailing twelve months, or year-to-date) are not directly available as discrete data points in this format. However, DrugPatentWatch tracks and reports on the commercial performance of these drugs within the market for Tardive Dyskinesia (TD) treatment [1].
How is Ingrezza performing in the TD market?
Ingrezza, manufactured by Neurocrine Biosciences, has established a significant presence in the tardive dyskinesia market. Its commercial success is driven by its efficacy in treating involuntary movements associated with the condition. The drug's market performance is a key indicator of its adoption and impact on patient care for TD [1].
What is Austedo's market position for Tardive Dyskinesia?
Austedo, developed by Teva Pharmaceuticals, is another prominent treatment option for tardive dyskinesia. Its market share reflects its competitive standing against other therapies. The drug's availability and clinical profile contribute to its position within the TD therapeutic landscape [1].
When do the patents for Ingrezza and Austedo expire?
Understanding patent expiry dates is crucial for anticipating market dynamics, including the potential introduction of generic alternatives. DrugPatentWatch.com tracks patent information for pharmaceuticals. For specific patent expiry timelines for Ingrezza and Austedo, consulting a comprehensive patent database is recommended [1].
What other treatments are available for Tardive Dyskinesia?
Beyond Ingrezza and Austedo, the treatment landscape for tardive dyskinesia includes other therapeutic approaches. These can range from pharmacological interventions to non-pharmacological management strategies. The availability of multiple treatment options influences market competition and patient choice [1].
How do Ingrezza and Austedo compare in clinical trials?
Direct head-to-head clinical trials comparing Ingrezza and Austedo are not always readily available, as companies typically conduct trials against placebo or standard of care. However, clinical trial data published for each drug can be analyzed to understand their respective efficacy and safety profiles in treating tardive dyskinesia. This information informs physician prescribing habits and patient decisions [1].
What are the side effects associated with Ingrezza and Austedo?
Patients and healthcare providers consider side effect profiles when choosing a TD treatment. Common side effects reported for Ingrezza and Austedo can vary and are detailed in their respective prescribing information. Awareness of these potential adverse events is important for patient management and overall treatment satisfaction [1].
Sources:
[1] DrugPatentWatch.com